Compared with docetaxel, pembrolizumab showed a median OS of 10.4 vs. 8.5 months (HR 0.71, 95% CI 0.58–0.88) at the approval dose of 2 mg/kg in NSCLC patients whose PD-L1 expression is 1% or above in tumor cells (7). Here, CD274 is linked to neoplasm.